ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

CINGW Cingulate Inc

0,0218
0,0002 (0,93%)
10 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cingulate Inc CINGW NASDAQ Warrant
  Variation Action Variation Action% Cours Dernier Dernier échange
0,0002 0,93% 0,0218 22:00:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,0218 0,0218 0,0218 0,0218 0,0216
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/5/202413:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202413:10EDGAR2Form 8-K - Current report
08/5/202413:00GLOBECingulate Reports First Quarter 2024 Financial Results and..
30/4/202411:45GLOBEPeter J. Werth, Successful Pharma Entrepreneur,..
16/4/202423:00GLOBECingulate to Participate in Planet MicroCap Showcase: Vegas..
01/4/202414:00GLOBECingulate Inc. Reports Fourth Quarter and Full Year 2023..
19/3/202421:45GLOBECingulate to Participate in Benzinga All Live Access Event
06/3/202412:45GLOBECingulate to Attend DCAT Week 2024 in New York City
13/2/202412:45GLOBECingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff..
06/2/202422:15GLOBECingulate Announces Closing of $7.5 Million Public Offering
02/2/202415:15GLOBECingulate Announces Pricing of $7.5 Million Public Offering
29/1/202414:00GLOBELongtime Cingulate Controller Jennifer Callahan Promoted to..
29/1/202412:45GLOBEWerth Family Investment Associates Converts Remaining $3.3M..
01/12/202315:00GLOBECingulate Receives Guidance from FDA on Path Forward for..
13/11/202322:15GLOBECingulate Inc. Reports Third Quarter 2023 Financial..
17/10/202320:22GLOBECingulate to Host CNS Key Opinion Leader Panel in New York..
21/9/202319:30GLOBECingulate Inc. to Present at the LD Micro Main Event XVI
13/9/202322:15GLOBECingulate Announces Closing of $4.0 Million Public Offering
11/9/202315:22GLOBECingulate Announces Pricing of $4.0 Million Public Offering
11/9/202312:00GLOBECingulate Announces Detailed Trial Results from Phase 3..
08/9/202322:31GLOBEWerth Family Investment Associates Converts $5.8 Million of..
05/9/202314:00GLOBECingulate Announces Presentation of Full Trial Results from..
14/8/202322:15GLOBECingulate Inc. Reports Second Quarter 2023 Financial..
11/7/202314:00GLOBECingulate Announces Positive Top-Line Results from Phase 3..
29/6/202314:00GLOBECingulate Successfully Manufactures Clinical Supply –..
14/6/202321:45GLOBECingulate to Participate in the Healthcare Virtual..
08/6/202313:00GLOBECingulate Completes Phase 3 Adult Trial of CTx-1301..
25/5/202321:55GLOBECingulate to Present at 13th Annual LD Micro Invitational